Table 5 |
|||
|
Sensitivity, Specificity, and PPV of anti-citrullinated antibodies and RF isotypes for the overall JIA population and JIA subtypes |
|||
|
Sensitivity (%) With 95%CI |
Specificity (%) With 95% CI |
PPV (%) With 95% CI |
|
|
|
|||
|
Anti-Citrullinated Fibrinogen Antibodies (> 0.59OD) |
|||
|
Overall |
32.3 (23.3-42.7) |
84.2 (59.5-95.8) |
91.2 (75.2-97.7) |
|
Poly RF-positive |
81.3 (53.7-95.0) |
78.8 (69.2-86.1) |
38.2 (22.7-56.4) |
|
Poly RF-negative |
30.6 (16.9-48.3) |
70.9 (59.4-80.3) |
32.4 (18.0-50.6) |
|
Oligoarthritis |
24.0 (10.2-45.5) |
68.9 (58.1-78.0) |
17.6 (7.4-35.0) |
|
Systemic-Onset |
7.7 (0.4-37.9) |
67.6 (57.6-76.4) |
29.4 (0.1-17.1) |
|
Anti-Citrullinated α-Enolase Antibodies (> 0.91OD) |
|||
|
Overall |
9.4 (4.6-17.5) |
57.9 (34.0-78.9) |
52.9 (28.5-76.1) |
|
Poly RF-positive |
18.8 (5.0-46.3) |
85.9 (77.1-91.8) |
17.6 (4.6-44.2) |
|
Poly RF-negative |
5.6 (1.0-20.0) |
70.9 (59.4-80.3) |
11.8 (2.1-37.7) |
|
Oligoarthritis |
0 |
81.1 (71.2-88.3) |
0 |
|
Systemic-Onset |
7.7 (0.4-37.9) |
84.3 (75.5-90.5) |
5.9 (0.3-31.0) |
|
IgG anti-CCP antibodies (> 20U) |
|||
|
Overall |
14.6 (8.5-23.6) |
94.7 (71.9-99.7) |
93.3 (66.0-99.7) |
|
Poly RF-positive |
56.3 (30.6-79.2) |
93.9 (86.8-97.5) |
60.0 (32.9-82.5) |
|
Poly RF-negative |
13.9 (5.2-30.3) |
87.3 (77.5-93.4) |
33.3 (13.0-61.3) |
|
Oligoarthritis |
0 |
83.3 (73.7-90.0) |
0 |
|
Systemic-Onset |
0 |
85.3 (76.6-91.2) |
0 |
|
IgA anti-CCP antibodies (> 0.16OD) |
|||
|
Overall |
10.4 (5.4-18.7) |
84.2 (59.5-95.8) |
76.9 (46.0-93.8) |
|
Poly RF-positive |
25.0 (8.3-52.6) |
90.9 (83.0-95.5) |
30.8 (10.3-61.1) |
|
Poly RF-negative |
16.7 (6.9-33.5) |
91.1 (82.0-96.1) |
46.2 (20.4-73.9) |
|
Oligoarthritis |
0 |
85.6 (76.2-91.8) |
0 |
|
Systemic-Onset |
0 |
87.3 (78.8-92.8) |
0 |
|
IgM Anti-CCP Antibodies (> 0.45OD) |
|||
|
Overall |
16.7 (10.1-26.0) |
73.7 (48.6-89.9) |
76.2 (52.5-90.9) |
|
Poly RF-positive |
31.3 (12.1-58.5) |
83.8 (74.8-90.2) |
23.8 (9.1-47.5) |
|
Poly RF-negative |
16.7 (6.9-33.5) |
91.1 (82.0-96.1) |
46.2 (20.4-73.9) |
|
Oligoarthritis |
0 |
76.7 (66.3-84.7) |
0 |
|
Systemic-Onset |
7.7 (0.4-37.9) |
80.4 (71.1-87.3) |
4.8 (0.2-25.9) |
|
IgA RF (> 6U) |
|||
|
Overall |
15.6 (9.3-24.8) |
84.2 (59.5-95.8) |
83.3 (57.7-95.6) |
|
Poly RF-positive |
62.5 (35.9-83.7) |
91.9 (84.2-96.2) |
55.6 (31.3-77.6) |
|
Poly RF-negative |
11.1 (3.6-27.0) |
82.2 (71.7-89.6) |
22.2 (7.4-48.1) |
|
Oligoarthritis |
0 |
80.0 (70.0-87.4) |
0 |
|
Systemic-Onset |
7.7 (0.4-37.9) |
83.3 (74.4-89.7) |
5.6 (0.3-29.4) |
|
IgM RF (> 6U) |
|||
|
Overall |
47.9 (37.7-58.3) |
63.1 (38.6-82.8) |
86.8 (74.0-94.1) |
|
Poly RF-positive |
100.0 (75.9-100.0) |
62.6 (52.3-72.0) |
30.2 (18.7-44.5) |
|
Poly RF-negative |
47.2 (30.8-64.7) |
54.4 (42.9-65.5) |
32.1 (20.3-46.4) |
|
Oligoarthritis |
20.0 (7.6-41.3) |
46.7 (36.2-57.4) |
9.4 (3.5-21.4) |
|
Systemic-Onset |
61.5 (32.3-84.9) |
55.9 (45.7-65.6) |
15.1 (7.2-28.1) |
|
|
|||
|
Anti-CCP antibodies: anti-cyclic citrullinated peptide antibodies; OD: optical density; CI: confidence interval; PPV: positive predictive value; RF: rheumatoid factor; U: units. Subtypes with small sample size were not included in the subtype analysis. |
|||
|
Gilliam et al. Pediatric Rheumatology 2011 9:8 doi:10.1186/1546-0096-9-8 |
|||
